Champions Oncology (CSBR) Competitors

$5.99 -0.02 (-0.33%)

Closing price 05/26/2026 04:00 PM Eastern

Extended Trading

$5.97 -0.02 (-0.33%)

As of 06:41 AM Eastern

CSBR vs. USNA, SIGA, ORGO, SRZN, and SLN

Should you buy Champions Oncology stock or one of its competitors? MarketBeat compares Champions Oncology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Champions Oncology include USANA Health Sciences (USNA), Siga Technologies (SIGA), Organogenesis (ORGO), Surrozen (SRZN), and Silence Therapeutics (SLN). These companies are all part of the "med - drugs" industry.

How does Champions Oncology compare to USANA Health Sciences?

USANA Health Sciences (NYSE:USNA) and Champions Oncology (NASDAQ:CSBR) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, media sentiment, risk, valuation, profitability, analyst recommendations and institutional ownership.

USANA Health Sciences has a net margin of 0.96% compared to Champions Oncology's net margin of -3.94%. USANA Health Sciences' return on equity of 6.21% beat Champions Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
USANA Health Sciences	0.96%	6.21%	4.50%
Champions Oncology	-3.94%	-57.31%	-7.51%

In the previous week, USANA Health Sciences had 2 more articles in the media than Champions Oncology. MarketBeat recorded 2 mentions for USANA Health Sciences and 0 mentions for Champions Oncology. USANA Health Sciences' average media sentiment score of 1.00 beat Champions Oncology's score of 0.00 indicating that USANA Health Sciences is being referred to more favorably in the media.

Company	Overall Sentiment
USANA Health Sciences	Positive
Champions Oncology	Neutral

USANA Health Sciences has higher revenue and earnings than Champions Oncology. Champions Oncology is trading at a lower price-to-earnings ratio than USANA Health Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
USANA Health Sciences	$925.94M	0.37	$10.76M	$0.47	39.11
Champions Oncology	$56.94M	1.46	$4.70M	-$0.16	N/A

USANA Health Sciences has a beta of 0.77, indicating that its share price is 23% less volatile than the broader market. Comparatively, Champions Oncology has a beta of 0.42, indicating that its share price is 58% less volatile than the broader market.

54.3% of USANA Health Sciences shares are owned by institutional investors. Comparatively, 41.3% of Champions Oncology shares are owned by institutional investors. 0.8% of USANA Health Sciences shares are owned by insiders. Comparatively, 47.0% of Champions Oncology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
USANA Health Sciences	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Champions Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

USANA Health Sciences beats Champions Oncology on 12 of the 14 factors compared between the two stocks.

How does Champions Oncology compare to Siga Technologies?

Champions Oncology (NASDAQ:CSBR) and Siga Technologies (NASDAQ:SIGA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Champions Oncology has a beta of 0.42, suggesting that its share price is 58% less volatile than the broader market. Comparatively, Siga Technologies has a beta of 0.93, suggesting that its share price is 7% less volatile than the broader market.

Siga Technologies has higher revenue and earnings than Champions Oncology. Champions Oncology is trading at a lower price-to-earnings ratio than Siga Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Champions Oncology	$56.94M	1.46	$4.70M	-$0.16	N/A
Siga Technologies	$93.78M	3.57	$23.28M	$0.27	17.30

Siga Technologies has a net margin of 21.58% compared to Champions Oncology's net margin of -3.94%. Siga Technologies' return on equity of 10.60% beat Champions Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Champions Oncology	-3.94%	-57.31%	-7.51%
Siga Technologies	21.58%	10.60%	8.94%

In the previous week, Siga Technologies had 1 more articles in the media than Champions Oncology. MarketBeat recorded 1 mentions for Siga Technologies and 0 mentions for Champions Oncology. Siga Technologies' average media sentiment score of 0.45 beat Champions Oncology's score of 0.00 indicating that Siga Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
Champions Oncology	Neutral
Siga Technologies	Neutral

41.3% of Champions Oncology shares are owned by institutional investors. Comparatively, 55.4% of Siga Technologies shares are owned by institutional investors. 47.0% of Champions Oncology shares are owned by insiders. Comparatively, 2.7% of Siga Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Champions Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Siga Technologies	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Siga Technologies beats Champions Oncology on 13 of the 14 factors compared between the two stocks.

How does Champions Oncology compare to Organogenesis?

Champions Oncology (NASDAQ:CSBR) and Organogenesis (NASDAQ:ORGO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, media sentiment, dividends, earnings and valuation.

Organogenesis has a consensus target price of $8.50, suggesting a potential upside of 219.55%. Given Organogenesis' stronger consensus rating and higher probable upside, analysts plainly believe Organogenesis is more favorable than Champions Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Champions Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Organogenesis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Organogenesis has a net margin of -0.84% compared to Champions Oncology's net margin of -3.94%. Organogenesis' return on equity of 9.63% beat Champions Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Champions Oncology	-3.94%	-57.31%	-7.51%
Organogenesis	-0.84%	9.63%	4.76%

In the previous week, Organogenesis had 2 more articles in the media than Champions Oncology. MarketBeat recorded 2 mentions for Organogenesis and 0 mentions for Champions Oncology. Organogenesis' average media sentiment score of 0.37 beat Champions Oncology's score of 0.00 indicating that Organogenesis is being referred to more favorably in the news media.

Company	Overall Sentiment
Champions Oncology	Neutral
Organogenesis	Neutral

Organogenesis has higher revenue and earnings than Champions Oncology. Champions Oncology is trading at a lower price-to-earnings ratio than Organogenesis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Champions Oncology	$56.94M	1.46	$4.70M	-$0.16	N/A
Organogenesis	$512.59M	0.67	$37.03M	-$0.19	N/A

41.3% of Champions Oncology shares are held by institutional investors. Comparatively, 49.6% of Organogenesis shares are held by institutional investors. 47.0% of Champions Oncology shares are held by company insiders. Comparatively, 33.0% of Organogenesis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Champions Oncology has a beta of 0.42, suggesting that its share price is 58% less volatile than the broader market. Comparatively, Organogenesis has a beta of 1.31, suggesting that its share price is 31% more volatile than the broader market.

Summary

Organogenesis beats Champions Oncology on 13 of the 16 factors compared between the two stocks.

How does Champions Oncology compare to Surrozen?

Surrozen (NASDAQ:SRZN) and Champions Oncology (NASDAQ:CSBR) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, media sentiment, analyst recommendations, institutional ownership and profitability.

Surrozen has a beta of 0.59, meaning that its share price is 41% less volatile than the broader market. Comparatively, Champions Oncology has a beta of 0.42, meaning that its share price is 58% less volatile than the broader market.

66.6% of Surrozen shares are held by institutional investors. Comparatively, 41.3% of Champions Oncology shares are held by institutional investors. 31.7% of Surrozen shares are held by company insiders. Comparatively, 47.0% of Champions Oncology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Surrozen had 1 more articles in the media than Champions Oncology. MarketBeat recorded 1 mentions for Surrozen and 0 mentions for Champions Oncology. Surrozen's average media sentiment score of 0.00 equaled Champions Oncology'saverage media sentiment score.

Company	Overall Sentiment
Surrozen	Neutral
Champions Oncology	Neutral

Surrozen currently has a consensus price target of $42.00, indicating a potential upside of 60.49%. Given Surrozen's stronger consensus rating and higher probable upside, analysts plainly believe Surrozen is more favorable than Champions Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Surrozen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Champions Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Champions Oncology has a net margin of -3.94% compared to Surrozen's net margin of -4,810.50%. Champions Oncology's return on equity of -57.31% beat Surrozen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Surrozen	-4,810.50%	-4,055.04%	-154.08%
Champions Oncology	-3.94%	-57.31%	-7.51%

Champions Oncology has higher revenue and earnings than Surrozen. Champions Oncology is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Surrozen	$3.48M	87.31	-$242.03M	-$37.59	N/A
Champions Oncology	$56.94M	1.46	$4.70M	-$0.16	N/A

Summary

Surrozen beats Champions Oncology on 9 of the 16 factors compared between the two stocks.

How does Champions Oncology compare to Silence Therapeutics?

Silence Therapeutics (NASDAQ:SLN) and Champions Oncology (NASDAQ:CSBR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and media sentiment.

Champions Oncology has higher revenue and earnings than Silence Therapeutics. Champions Oncology is trading at a lower price-to-earnings ratio than Silence Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silence Therapeutics	$839K	373.83	-$88.61M	-$1.59	N/A
Champions Oncology	$56.94M	1.46	$4.70M	-$0.16	N/A

98.7% of Silence Therapeutics shares are held by institutional investors. Comparatively, 41.3% of Champions Oncology shares are held by institutional investors. 3.0% of Silence Therapeutics shares are held by company insiders. Comparatively, 47.0% of Champions Oncology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Silence Therapeutics had 2 more articles in the media than Champions Oncology. MarketBeat recorded 2 mentions for Silence Therapeutics and 0 mentions for Champions Oncology. Silence Therapeutics' average media sentiment score of 0.00 equaled Champions Oncology'saverage media sentiment score.

Company	Overall Sentiment
Silence Therapeutics	Neutral
Champions Oncology	Neutral

Silence Therapeutics has a beta of 1.52, meaning that its stock price is 52% more volatile than the broader market. Comparatively, Champions Oncology has a beta of 0.42, meaning that its stock price is 58% less volatile than the broader market.

Champions Oncology has a net margin of -3.94% compared to Silence Therapeutics' net margin of -8,943.86%. Champions Oncology's return on equity of -57.31% beat Silence Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silence Therapeutics	-8,943.86%	-105.34%	-52.79%
Champions Oncology	-3.94%	-57.31%	-7.51%

Silence Therapeutics currently has a consensus price target of $55.00, suggesting a potential upside of 728.31%. Given Silence Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Silence Therapeutics is more favorable than Champions Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silence Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Champions Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Silence Therapeutics beats Champions Oncology on 9 of the 16 factors compared between the two stocks.

Get Champions Oncology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CSBR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CSBR vs. The Competition

Export

Metric	Champions Oncology	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$83.46M	$3.05B	$6.44B	$12.35B
Dividend Yield	N/A	1.97%	2.76%	5.28%
P/E Ratio	-37.44	17.49	20.78	25.82
Price / Sales	1.46	341.57	526.87	70.42
Price / Cash	13.10	57.74	43.49	56.67
Price / Book	22.19	5.81	10.46	7.17
Net Income	$4.70M	$75.57M	$3.56B	$336.99M
7 Day Performance	0.62%	1.35%	2.35%	2.83%
1 Month Performance	-0.50%	-2.11%	2.04%	3.14%
1 Year Performance	1.01%	34.68%	35.52%	35.93%

Champions Oncology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CSBR Champions Oncology	0.0786 of 5 stars	$5.99 -0.3%	N/A	+3.9%	$83.46M	$56.94M	N/A	143
USNA USANA Health Sciences	2.8938 of 5 stars	$18.18 +4.1%	N/A	-37.5%	$322.55M	$925.26M	38.68	1,570	Positive News
SIGA Siga Technologies	1.081 of 5 stars	$4.49 +2.7%	N/A	-21.0%	$313.43M	$94.57M	16.63	40	High Trading Volume
ORGO Organogenesis	2.4399 of 5 stars	$2.55 +4.9%	$8.50 +233.3%	-8.3%	$312.68M	$564.17M	N/A	950
SRZN Surrozen	3.0109 of 5 stars	$27.05 +5.8%	$42.00 +55.3%	+228.8%	$296.88M	$3.48M	N/A	80

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CSBR) was last updated on 5/27/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Champions Oncology (CSBR) Competitors

CSBR vs. USNA, SIGA, ORGO, SRZN, and SLN

How does Champions Oncology compare to USANA Health Sciences?

Summary

How does Champions Oncology compare to Siga Technologies?

Summary

How does Champions Oncology compare to Organogenesis?

Summary

How does Champions Oncology compare to Surrozen?

Summary

How does Champions Oncology compare to Silence Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CSBR vs. The Competition

Champions Oncology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Champions Oncology (CSBR) Competitors

CSBR vs. USNA, SIGA, ORGO, SRZN, and SLN

How does Champions Oncology compare to USANA Health Sciences?

Is USNA or CSBR more profitable?

Does the media favor USNA or CSBR?

Which has higher earnings & valuation, USNA or CSBR?

Which has more risk & volatility, USNA or CSBR?

Do insiders & institutionals hold more shares of USNA or CSBR?

Do analysts rate USNA or CSBR?

Summary

How does Champions Oncology compare to Siga Technologies?

Which has more volatility & risk, CSBR or SIGA?

Which has better valuation & earnings, CSBR or SIGA?

Is CSBR or SIGA more profitable?

Does the media refer more to CSBR or SIGA?

Do insiders and institutionals believe in CSBR or SIGA?

Do analysts recommend CSBR or SIGA?

Summary

How does Champions Oncology compare to Organogenesis?

Do analysts recommend CSBR or ORGO?

Is CSBR or ORGO more profitable?

Does the media favor CSBR or ORGO?

Which has better earnings and valuation, CSBR or ORGO?

Do institutionals & insiders have more ownership in CSBR or ORGO?

Which has more volatility and risk, CSBR or ORGO?

Summary

How does Champions Oncology compare to Surrozen?

Which has more volatility and risk, SRZN or CSBR?

Do institutionals and insiders hold more shares of SRZN or CSBR?

Does the media favor SRZN or CSBR?

Do analysts prefer SRZN or CSBR?

Is SRZN or CSBR more profitable?

Which has better earnings & valuation, SRZN or CSBR?

Summary

How does Champions Oncology compare to Silence Therapeutics?

Which has higher earnings & valuation, SLN or CSBR?

Do institutionals & insiders have more ownership in SLN or CSBR?

Does the media refer more to SLN or CSBR?

Which has more risk and volatility, SLN or CSBR?

Is SLN or CSBR more profitable?

Do analysts prefer SLN or CSBR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CSBR vs. The Competition

Champions Oncology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools